Jamshedpur Reporter

Rheumatoid Arthritis (RA) Market to Observe Stupendous Growth During the Forecast Period (2019-32) | Key Companies – Gilead, Galapagos, R-Pharm, Merck, Roche, Pfizer, GlaxoSmithKline

 Breaking News
  • No posts were found

Rheumatoid Arthritis (RA) Market to Observe Stupendous Growth During the Forecast Period (2019-32) | Key Companies – Gilead, Galapagos, R-Pharm, Merck, Roche, Pfizer, GlaxoSmithKline

August 08
20:15 2022
Rheumatoid Arthritis (RA) Market to Observe Stupendous Growth During the Forecast Period (2019-32) | Key Companies - Gilead, Galapagos, R-Pharm, Merck, Roche, Pfizer, GlaxoSmithKline
Delveinsight Business Research LLP
As per DelveInsight, the Rheumatoid Arthritis (RA) market size is expected to increase in the coming years due to the increase in the number of geriatric people, increase in market penetration of advanced therapies, readily uptake of current as well as emerging therapies with convenient patient RoA, and increasing awareness about this disorder.

DelveInsight’s “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Rheumatoid Arthritis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Rheumatoid Arthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Rheumatoid Arthritis: An Overview

Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints. RA is the result of an immune response in which the body’s immune system attacks its own healthy cells, and the specific causes of RA are still unknown.

Rheumatoid Arthritis is more common in women, and about 75% of Rheumatoid Arthritis (RA) patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.

Rheumatoid Arthritis Market Key Facts

  • The total prevalent cases of Rheumatoid Arthritis (RA) in the 7MM were observed to be 4,356,700+ in 2017, which are estimated to rise during the study period.

  • The United States, in 2017, accounted for the highest number of cases in the 7MM, i.e., 1,333,200+ prevalent cases. Apart from this, in EU-5 countries, the highest number of cases of Rheumatoid Arthritis (RA) was in Germany in 2017. 

  • According to the analysis, women are 2-3 times more frequently diagnosed with Rheumatoid Arthritis than men.

  • In the 7MM, the total gender-specific prevalent cases of Rheumatoid Arthritis were 1,007,600+ for men and 2,818,000+ for women in the year 2017.

Rheumatoid Arthritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Rheumatoid Arthritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Rheumatoid Arthritis market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Rheumatoid Arthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Rheumatoid Arthritis Epidemiology Segmentation

  • Total Diagnosed Prevalent Cases 

  • Total Prevalent Cases 

  • Severity-specific Prevalent Cases 

  • Gender-specific Prevalent Cases 

  • Age-specific Prevalent Cases 

  • Line-Wise Treated Cases 

  • Patients on targeted therapies 

Rheumatoid Arthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Rheumatoid Arthritis market or expected to get launched during the study period. The analysis covers Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Rheumatoid Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

Rheumatoid Arthritis Therapeutics Analysis

The dynamics of the Rheumatoid Arthritis (RA) market are anticipated to change in the coming years owing to the increasing awareness and expected increase in investment in R&D activities.

Some of the key companies in the Rheumatoid Arthritis (RA) market include:

  • GlaxoSmithKline

  • Gilead 

  • Galapagos NV

  • R-Pharm

  • Merck KGaA

  • Roche

  • Pfizer

And many others.

Rheumatoid Arthritis (RA) Therapies Covered in the report:

  • Filgotinib

  • Olokizumab

  • Evobrutinib

  • Fenebrutinib

  • PF-06650833

  • PF-06651600

  • Ozoralizumab (TS-152)

And many others.

Given the large number of potential medicines being studied for the treatment of Rheumatoid Arthritis, it is reasonable to expect that the treatment space will undergo significant change in the coming years.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Rheumatoid Arthritis Competitive Intelligence Analysis

4. Rheumatoid Arthritis Market Overview at a Glance

5. Rheumatoid Arthritis Disease Background and Overview

6. Rheumatoid Arthritis Patient Journey

7. Rheumatoid Arthritis Epidemiology and Patient Population

8. Rheumatoid Arthritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Rheumatoid Arthritis Unmet Needs

10. Key Endpoints of Rheumatoid Arthritis Treatment

11. Rheumatoid Arthritis Marketed Products

12. Rheumatoid Arthritis Emerging Therapies

13. Rheumatoid Arthritis Seven Major Market Analysis

14. Attribute Analysis

15. Rheumatoid Arthritis Market Outlook (7 major markets)

16. Rheumatoid Arthritis Access and Reimbursement Overview

17. KOL Views on the Rheumatoid Arthritis Market.

18. Rheumatoid Arthritis Market Drivers

19. Rheumatoid Arthritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Neurological Diagnostic and Monitoring Equipment Market
“Neurological Diagnostic and Monitoring Equipment Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Neurological Diagnostic and Monitoring Equipment. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Neurological Diagnostic and Monitoring Equipment market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/